Business Context and Reporting Period
GRI Bio, Inc. filed a Form 8-K on August 25, 2023. The filing reports a Regulation FD disclosure and furnishes the company’s corporate presentation dated August 25, 2023 as Exhibit 99.1. GRI Bio is an emerging growth company, and its common stock trades on The Nasdaq Capital Market under the symbol GRI.
Financial Metrics and Capital Resources
The filing text does not provide financial statements, revenue, profit or loss, cash flow, margins, debt, liquidity balances, or other quantitative financial metrics.
Material Changes Versus Prior Period
The filing does not report financial or operational changes versus a prior comparable period. It only identifies the furnishing of the corporate presentation.
Guidance, Outlook, Risks, and Unusual Items
- The corporate presentation is furnished under Item 7.01 and is not deemed filed for purposes of Section 18 of the Exchange Act.
- The presentation is not incorporated by reference into other filings unless expressly stated in a subsequent filing.
- The contents of Exhibit 99.1 are not included in the provided filing text; therefore, any guidance, clinical or business updates, risks, contingencies, or unusual items discussed in the presentation cannot be assessed.
Investor Verification Items
- Review Exhibit 99.1 for the company’s business strategy, development programs, clinical or regulatory updates, and forward-looking statements.
- Verify any financial, cash runway, financing, or capital requirements disclosed in the presentation, as these figures are not included in the filing text provided.
- Assess the assumptions, risks, and disclaimers supporting any outlook or projections in the presentation.
- Note that the furnished presentation may not have the same filing status or liability treatment as filed Exchange Act materials.